albinaglisic / Shutterstock.com
Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of Endo Pharmaceutical's medications from entering the market, the US Federal Trade Commission has ruled.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Impax, US Federal Trade Commission, Endo Pharmaceuticals, Opana, oxymorphone